These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 9359008)

  • 21. Strategies for managing refractoriness to platelet transfusions.
    Dan ME; Schiffer CA
    Curr Hematol Rep; 2003 Mar; 2(2):158-64. PubMed ID: 12901147
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-HLA Class I alloantibodies in platelet transfusion refractoriness: From mechanisms and determinants to therapeutic prospects.
    Couvidou A; Rojas-Jiménez G; Dupuis A; Maître B
    Front Immunol; 2023; 14():1125367. PubMed ID: 36845153
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnosis and treatment of immunological platelet refractoriness by histocompatibility.
    Fagundes IS; Franz JM; Jobim MS; Arend A; Merzoni J; Cardone JM; Gil B; Sekine L; Jobim LF
    Hum Immunol; 2020 May; 81(5):197-201. PubMed ID: 32067841
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of HLA- and HPA--matched platelets in alloimmunized patients.
    Kekomäki R
    Vox Sang; 1998; 74 Suppl 2():359-63. PubMed ID: 9704468
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical aspects of platelet transfusions.
    Murphy MF; Waters AH
    Blood Coagul Fibrinolysis; 1991 Apr; 2(2):389-96. PubMed ID: 1893071
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frequency and causes of refractoriness in multiply transfused patients.
    Legler TJ; Fischer I; Dittmann J; Simson G; Lynen R; Humpe A; Riggert J; Schleyer E; Kern W; Hiddemann W; Köhler M
    Ann Hematol; 1997 Apr; 74(4):185-9. PubMed ID: 9174547
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Platelet transfusion refractoriness and effective management of platelet alloimmunization].
    Amemiya Y
    Nihon Rinsho; 1997 Sep; 55(9):2392-8. PubMed ID: 9301306
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful treatment of platelet transfusion refractoriness: the use of platelet transfusions matched for both human leucocyte antigens (HLA) and human platelet alloantigens (HPA) in alloimmunized patients with leukaemia.
    Kekomäki S; Volin L; Koistinen P; Koivunen E; Koskimies S; Ruutu T; Timonen T; Kekomäki R
    Eur J Haematol; 1998 Feb; 60(2):112-8. PubMed ID: 9508352
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Platelet transfusion refractoriness due to HLA alloimmunization: Evolving paradigms in mechanisms and management.
    Panch SR; Guo L; Vassallo R
    Blood Rev; 2023 Nov; 62():101135. PubMed ID: 37805287
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The challenge of platelet alloimmunization: management and prevention.
    Kickler TS
    Transfus Med Rev; 1990 Oct; 4(4 Suppl 1):8-18. PubMed ID: 2134640
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Red blood cell alloantibodies are associated with increased alloimmunization against human leukocyte antigens.
    Belizaire R; Mack J; Kadauke S; Kim Y; Saidman S; Makar RS
    Transfusion; 2019 Jul; 59(7):2256-2263. PubMed ID: 30980544
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In utero exposure to alloantigens primes alloimmunization to platelet transfusion in mice.
    Poston JN; Jash A; Hannan LM; Hay AM; Usaneerungrueng C; Howie HL; Kapp LM; Zimring JC
    Transfusion; 2021 Mar; 61(3):687-691. PubMed ID: 33336414
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New paradigms in the management of alloimmune refractoriness to platelet transfusions.
    Vassallo RR
    Curr Opin Hematol; 2007 Nov; 14(6):655-63. PubMed ID: 17898571
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Platelet allo-antibodies identification strategies for preventing and managing platelet refractoriness].
    Basire A; Picard C
    Transfus Clin Biol; 2014 Nov; 21(4-5):193-206. PubMed ID: 25277423
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human Leukocyte Antigen Class I Antibodies and Response to Platelet Transfusion in Patients Undergoing Liver Transplantation.
    Wong M; Narra R; Selim M; Zimmerman MA; Kim J; Padmanabhan A; Hong JC
    J Surg Res; 2020 Nov; 255():99-105. PubMed ID: 32543385
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of platelet refractoriness in oncohematologic patients.
    Ferreira AA; Zulli R; Soares S; Castro Vd; Moraes-Souza H
    Clinics (Sao Paulo); 2011; 66(1):35-40. PubMed ID: 21437433
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HPA antibodies in Algerian multitransfused patients: Prevalence and involvement in platelet refractoriness.
    Brouk H; Bertrand G; Zitouni S; Djenouni A; Martageix C; Griffi F; Kaplan C; Ouelaa H
    Transfus Apher Sci; 2015 Jun; 52(3):295-9. PubMed ID: 25620758
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The alloimmunized patient: effective transfusion support and newer experimental approaches.
    Pamphilon DH
    Blood Coagul Fibrinolysis; 1992 Oct; 3(5):651-4. PubMed ID: 1450334
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Platelet transfusions irradiated with ultraviolet-B light may have a role in reducing recipient alloimmunization.
    Tandy NP; Pamphilon DH
    Blood Coagul Fibrinolysis; 1991 Apr; 2(2):383-8. PubMed ID: 1893070
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: a prospective, randomized trial.
    van Marwijk Kooy M; van Prooijen HC; Moes M; Bosma-Stants I; Akkerman JW
    Blood; 1991 Jan; 77(1):201-5. PubMed ID: 1984797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.